Dr Marcia Brose presents data on a randomised phase III study, DECISION, during a press conference at the 2013 ASCO Annual Meeting.

The study found that the targeted drug sorafenib stalls disease progression by five months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine (RAI) therapy. If approved by the FDA, sorafenib would become the first new active drug for this form of thyroid cancer in 40 years.

Visit ecancerNews to read more